Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics announced today that the latest findings of its research team is on line on the Cancers website. By using an in vitro (THP-1 cell line) and ex vivo model system (human monocyte-derived dendritic cells), the team was able to demonstrate that ATP128 relies on both the cell-penetrating peptide and TLR agonist domain present in the construct to activate the NF-κB and IRF3 pathways, in a self-adjuvanting manner. Importantly, it was demonstrated that ATP128 is the first therapeutic vaccine able to activate human DCs through TLR2 and TLR4.